Dorsal Root Ganglion Stimulation as a Potentially Effective Treatment for Painful Hereditary and Idiopathic Axonal Polyneuropathy: A Retrospective Case Series. Issue 2 (14th February 2019)

• Record Type: Journal Article
• Authors: Ho, Kwo Wei David; Rempe, Torge; Jerath, Nivedita; Antony, Ajay
• Is Part Of: Neuromodulaton. Volume 23:Issue 2(2020)
• Page Start: 234
• Page End: 238
• Publication Date: 2019-02-14
• Subjects: Axonal polyneuropathy -- dorsal root ganglion stimulation -- hereditary polyneuropathy -- idiopathic polyneuropathy -- painful polyneuropathy; Central nervous system -- Physiology -- Periodicals; Central nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ner.12924
• Languages: English
• ISSNs: 1094-7159

Abstract

Abstract : Objectives: Dorsal root ganglion (DRG) stimulation has been demonstrated to be effective in treating painful diabetic polyneuropathy in a small case series. However, diabetic polyneuropathy only accounts for 41% of all polyneuropathies and the efficacy of DRG on other types of polyneuropathy is unclear. The objective of this study is to evaluate the efficacy of DRG stimulation in treating painful hereditary and idiopathic axonal polyneuropathy. Materials and Methods: This is a monocentric retrospective case series. Two subjects with painful hereditary axonal polyneuropathy and two subjects with painful chronic idiopathic axonal polyneuropathy who underwent DRG stimulation trials were included in this study. All subjects were evaluated independently by neuromuscular neurologists with eletrophysiological studies and genetic testing. Permanent DRG stimulator was implanted if significant pain relief (>50%) was achieved over the trial period. Pain level were evaluated at baseline, during the trial, after the permanent implantation and at one, three, and six months. Results: Pain was significantly reduced after the DRG stimulator trial with an average VAS reduction of 6.00 ± 2.83, or 65 ± 26.77% ( p = 0.024). Three subjects subsequently underwent permanent DRG stimulator implantation. Pain remained significantly reduced after the permanent implantation. The average VAS reduction was 6.33 ± 2.31, or 67.5 ± 20.46% after permanent DRG implantation ( p = 0.042), 7.67 ± 2.31, or 80.83 ± 15.88% at one month ( p = 0.029), and 7.00 ± 2.00 or 74.17 ± 14.21% at three and six months ( p = 0.026). No complications were observed. Conclusion: This small retrospective study suggests that DRG stimulation may be a safe and effective treatment for painful hereditary and idiopathic axonal polyneuropathy.